The effect of probiotic treatment in patients with collagenous colitis is unknown.
In this study, doctors evaluated the clinical effect of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis subsp. lactis BB-12 (AB-Cap-10) in these patients.
A total of 29 patients with collagenous colitis and diarrhea were enrolled in a randomized double-blind placebo-controlled study.
Of these, 21 patients received AB-Cap-10 and 8 patients received placebo for 12 weeks.
|The probiotic group had a reduction in bowel frequency.|
|Inflammatory Bowel Diseases|
The team set the primary end point as a reduction in bowel frequency per week of greater than or equal to 50%.
The secondary end points were changes in bowel frequencies, stool consistency, stool weight, histopathology, and abdominal bloating and pain.
The doctors found that a non-significant reduction in bowel frequency in the probiotic group compared to the placebo group (29% vs 13%).
They were also unable to identify any differences between treatments for the secondary end points.
However, post hoc analysis identified a significant median reduction in bowel frequency per week from 32 to 23 in the probiotic group.
There was also a reduction in the number of days with liquid stools per week from 6 days to 1 day, and an increase in number of days with solid stools.
Dr Signe Wildt's team concluded, "AB-Cap-10 had no significant effect on the chosen end points".
"Post hoc analysis demonstrated amelioration of clinical symptoms in the AB-Cap-10 group, indicating that probiotic treatment may potentially influence the disease course of collagenous colitis ".